Source comparison
Mechanism Differences: GHRH vs Ghrelin Pathway Activation
CJC-1295 no DAC is a GHRH analog that binds to GHRH receptors on somatotroph cells in the anterior pituitary, triggering cyclic AMP signaling that upregulates GH synthesis and secretion. The modified structure (specifically the addition of four amino acids to
This comparison does not assign a generated winner or score.
- CJC-1295 no DAC is a GHRH analog that binds to GHRH receptors on somatotroph cells in the anterior pituitary, triggering cyclic AMP signaling that upregulates GH synthesis and secretion. The modified structure (specifically the addition of four amino acids to the natural GHRH 1-29 sequence) extends stability against enzymatic degradation by dipeptidyl peptidase-4 (DPP-4). CJC-1295 no DAC has a half-life of approximately 30 minutes, necessitating dosing 2–3 times daily.
- Ipamorelin acts as a selective ghrelin receptor agonist, binding to the growth hormone secretagogue receptor type 1a (GHS-R1a). Activation of GHS-R1a triggers calcium ion influx into somatotroph cells, stimulating GH release through a pathway entirely independent of GHRH signaling. Ipamorelin's selectivity is notable: unlike earlier ghrelin mimetics (GHRP-2, GHRP-6), it doesn't significantly elevate cortisol, prolactin, or appetite-stimulating signals. Plasma GH peaks occur 15–30 minutes post-injection and return to baseline within 2 hours.
- The critical insight: these peptides don't replace one another. They amplify one another when used simultaneously. GHRH and ghrelin pathways converge at the somatotroph but involve distinct intracellular signaling cascades. Co-administration produces synergistic GH release exceeding the additive effect of either compound alone.